Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of PEG-rhGH or rhGH in Chinese children with short stature
ChiCTR2300070431Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peg-somatropin and somatropin in growth disorder, growth hormone deficiency (GHD), Idiopathic Short Stature (ISS) and 5 more, sponsored by Tongji Hospital. Primary endpoint: Safety. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
peg-somatropinsomatropin
03
Conditions
growth disordergrowth hormone deficiency (GHD)Idiopathic Short Stature (ISS)Small for gestational age (SGA)Turner syndrome (TS)
Beyond the preview
Go deeper on ChiCTR2300070431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070431.